Aura Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Aura Biosciences, Inc. has filed an exit amendment to its Schedule 13D, reporting the repurchase of 6,922,870 shares of common stock by the issuer from Matrix Fund.
NASDAQ
SCHEDULE 13D/A: Matrix Capital Management Discloses 11.17% Stake in Aura Biosciences and Enters 90-Day Lock-Up Agreement Post-Offering
Matrix Capital Management Company LP and David E. Goel have filed an amended Schedule 13D, disclosing a beneficial ownership of 11.17% in Aura Biosciences, Inc. and confirming a 90-day lock-up agreement following the company's recent 2025 Offering.